Actively Recruiting

Age: 18Years - 120Years
All Genders
ID02682667

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Led by National Cancer Institute (NCI) · Updated on 2026-06-05

500

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying biospecimens from adults with cancer, premalignant conditions, or immunodeficiencies that increase cancer risk to better understand why different cancers respond differently to treatment. The goal is to support immunotherapy research by analyzing biological samples and clinical data. This observational study is sponsored by the National Cancer Institute and aims to collect various samples for ongoing research. Participants will provide samples such as blood, apheresis products, tumor tissue, body fluids, bone marrow, skin, and mucosa for banking and laboratory studies. No experimental treatments will be given as part of this protocol. Some participants may undergo procedures like apheresis and bone marrow biopsy. Re-enrollment is allowed for a few participants. During the study, participants will have medical history reviews, physical exams, and blood and urine tests at least once. Imaging scans such as CT, MRI, PET, or ultrasound may be done to locate tumors. Participants will be contacted annually by phone to check on their health status. The study monitors ongoing sample acquisition and examines relationships between clinical factors, biospecimen features, and patient demographics. The trial may last until December 2032.

CONDITIONS

Brief Title

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Who Can Participate

Age: 18Years - 120Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of cancer, premalignant condition, or immunodeficiency increasing cancer risk
  • Age 18 years or older
  • ECOG performance status between 0 and 3
  • Ability and willingness to provide informed consent
  • For apheresis participants: hemoglobin ≥ 8 mg/dL, platelet count > 75 K/microL, weight ≥ 48 kg, and adequate venous access
Not Eligible

You will not qualify if you...

  • Active medical or psychological illnesses that increase risk
  • Inability to provide informed consent
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Sample Collection

Duration - Ongoing throughout participation

Participants provide various biospecimens such as blood, apheresis products, tumor tissue, body fluids, and others for banking and research studies.

Visits as needed for biospecimen collection

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

S

Scott M Norberg, D.O.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multi...

Multiple Myeloma

Actively Recruiting

1 location

Preoperative 3-D Virtual Resection Predicts Lung Function Af...

Non-small Cell Lung Cancer

Actively Recruiting

1 location

Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematolog...

Multiple Myeloma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here